3/13
05:53 pm
knte
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, DOOR, HMST
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, DOOR, HMST
3/13
11:49 am
knte
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
Low
Report
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
3/11
10:20 pm
knte
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - EVBG, TAST, ZFOX, KNTE
Neutral
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - EVBG, TAST, ZFOX, KNTE
3/8
08:26 am
knte
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Low
Report
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
3/5
12:30 pm
knte
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - KNTE, INBX, KAMN
Low
Report
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - KNTE, INBX, KAMN
3/1
04:54 pm
knte
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Kinnate Biopharma Inc. by XOMA Corporation
Low
Report
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Kinnate Biopharma Inc. by XOMA Corporation
3/1
08:45 am
knte
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories [Yahoo! Finance]
Low
Report
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories [Yahoo! Finance]
3/1
08:35 am
knte
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
Low
Report
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
3/1
08:35 am
knte
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
Medium
Report
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
3/1
08:35 am
knte
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
Low
Report
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
3/1
08:30 am
knte
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
Medium
Report
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
2/28
01:30 pm
knte
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
2/26
10:15 pm
knte
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates NGM, AA, HRT, KNTE
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates NGM, AA, HRT, KNTE
2/26
10:12 am
knte
Kinnate Biopharma Inc. (NASDAQ: KNTE) had its price target raised by analysts at Stifel Nicolaus from $1.50 to $2.59. They now have a "hold" rating on the stock.
Low
Report
Kinnate Biopharma Inc. (NASDAQ: KNTE) had its price target raised by analysts at Stifel Nicolaus from $1.50 to $2.59. They now have a "hold" rating on the stock.
2/22
06:44 am
knte
Kinnate Biopharma Inc. (NASDAQ: KNTE) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Low
Report
Kinnate Biopharma Inc. (NASDAQ: KNTE) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
2/21
10:13 am
knte
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DFS, COF, KNTE
Medium
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DFS, COF, KNTE
2/19
08:27 pm
knte
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, CTLT
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, CTLT
2/19
11:03 am
knte
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
Low
Report
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
2/17
09:45 am
knte
Private equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as well [Yahoo! Finance]
Low
Report
Private equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as well [Yahoo! Finance]
2/16
05:57 pm
knte
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.
Low
Report
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.
2/16
04:41 pm
knte
Health-Care Stocks Edge Higher -- Health Care Roundup [MarketWatch]
Low
Report
Health-Care Stocks Edge Higher -- Health Care Roundup [MarketWatch]
2/16
02:25 pm
knte
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
Low
Report
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
2/16
11:06 am
knte
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, FANG, HAYN, VINE
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, FANG, HAYN, VINE
2/16
09:09 am
knte
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
Low
Report
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
2/16
08:37 am
knte
Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share [Seeking Alpha]
Low
Report
Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share [Seeking Alpha]